Beijing Sungen Biomedical Technology Co., Ltd. with the mission of "Innovate to lead the future and benefit human health", is committed to developing FIC (First in class) antibody drugs, focusing on unmet clinical needs, and striving to become the world's leading antibody research and development (R & D) enterprise.
With excellent scientific and innovative drug R & D capabilities, Sungen has built a series of international standard technology platforms and original biological macromolecular R & D pipelines with great market potentials, involving innovative therapeutic drugs for cardiovascular and cerebrovascular diseases, tumors, neurodegenerative diseases and other indications.
